In regulatory filings, Better Therapeutics disclosed that its director Andrew Armanino bought 303K shares at $250K in common stock, director Geoffrey Parker bought 303K shares at $250K in common stock, and CEO Frank Karbe bought 242K share at $200K in common stock on April 10th. Shares of Better Therapeutics are up 9% afterhours as $1.36.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTTX:
- Better Therapeutics sells 7.878M shares at 82.5c in private placement
- Better Therapeutics price target lowered to $9 from $14 at Chardan
- Better Therapeutics reports Q4 EPS (37c), consensus (51c)
- Better Therapeutics, Inc. (BTTX) Q4 Earnings Cheat Sheet
- Better Therapeutics management to meet virtually with Lake Street